BUCHANG PHARMA released its semi-annual performance, with a net profit attributable to the parent company of 628 million yuan, a year-on-year increase of 171.24%
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, BUCHANG PHARMA disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 5.664 billion yuan, a year-on-year increase of 4.27%; net profit attributable to the parent company was 628 million yuan, a year-on-year increase of 171.24%; net profit excluding non-recurring gains and losses was 619 million yuan, a year-on-year increase of 180.04%; basic earnings per share were 0.5934 yuan. The company plans to distribute a cash dividend of 3.90 yuan (tax included) for every 10 shares
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments